There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Urogen Pharma Ltd (URGN), Pfizer (PFE) and Bausch Health Companies Inc (BHC) with bullish sentiments.
Urogen Pharma Ltd (URGN)
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Urogen Pharma Ltd, with a price target of $63. The company’s shares closed on Friday at $36.37, close to its 52-week low of $34.61.
Archila noted:
“We are reiterating our Buy rating on URGN shares after attending the American Urological Association (AUA) meeting this weekend where the company presented updated data (see pgs. 2-10) from its ongoing open-label Phase 3 OLYMPUS study for UGN-101 in patients with upper tract urothelial carcinoma (UTUC). In our view, there were two important takeaways from the presented data: (1) the 89% complete responder (CR) rate at 6 months for patients who respond to UGN-101 therapy, an encouraging sign of UGN-101’s overall durability; and (2) UGN-101’s kidney sparing ability in patients with un-resectable tumors as responders in this subpopulation also demonstrated durable CR rates out to 6 months.”
According to TipRanks.com, Archila has 0 stars on 0-5 star ranking scale with an average return of -8.9% and a 34.4% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Principia Biopharma Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Urogen Pharma Ltd with a $65 average price target, representing a 78.7% upside. In a report issued on April 24, H.C. Wainwright also reiterated a Buy rating on the stock with a $75 price target.
See today’s analyst top recommended stocks >>
Pfizer (PFE)
Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Pfizer today and set a price target of $53. The company’s shares closed on Friday at $41.39.
Chen commented:
“. This morning, PFE announced the approval of both Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) as the first and only treatment for either wild-type or hereditary transthyretuin amyloid cardiomyopathy (ATTR-CM) in the U.S.. We have been positive on this program with highly convincing Phase 3 data (30% reduction in mortality risk and 32% reduction in rate of CV-related hospitalizations versus placebo) and believe it has the potential for $1B+ in sales, noted in our previous quick take and deep dive note. We think the potential patient population and hence market opportunity are sorely underappreciated for Vyndaqel/Vyndamax.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 8.5% and a 38.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Amneal Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $47 average price target.
Bausch Health Companies Inc (BHC)
In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Bausch Health Companies Inc, with a price target of $41. The company’s shares closed on Friday at $23.44.
Rivkind Koffler observed:
“We were positively surprised by this announcement because we expected headwinds from the transition to cash pay within Ortho Dermatologics, and also believe it may be challenging for Bausch to achieve approximately $300M in revenue from its significant seven products after the delayed approval of Duobrii, which is expected to launch in June. We hypothesize the guidance raise could be attributed to the recent Trulance acquisition, coupled with the strength in Salix. We reiterate our Buy rating, which is predicated on continued execution against guidance targets and emerging visibility into longer-term growth.”
According to TipRanks.com, Koffler is a 3-star analyst with an average return of 2.7% and a 38.4% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Assertio Therapeutics Inc, and Eagle Pharmaceuticals Inc.
Currently, the analyst consensus on Bausch Health Companies Inc is a Moderate Buy with an average price target of $33, representing a 40.8% upside. In a report issued on April 25, Cantor Fitzgerald also maintained a Buy rating on the stock with a $32 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
